Psychopharmacology

, Volume 170, Issue 1, pp 33–41 | Cite as

Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice

  • Kennon M. Garrett
  • Garo Basmadjian
  • Ikhlas A. Khan
  • Brian T. Schaneberg
  • Thomas W. Seale
Original Investigation

Abstract

Rationale

Kava has been used for centuries by Pacific Islanders for its tranquilizing and sedative effects. Recent clinical trials suggest that kava has therapeutic value for the treatment of anxiety. Demonstration of kava's anxiolytic effects in animals under controlled conditions would provide additional support for its clinical potential as an anxiolytic and would facilitate investigation of its mechanism(s) of action.

Objectives

This study systematically characterized the acute dosage-dependent anxiolytic and sedative effects of kava extract in well established quantitative murine behavioral assays and compared kava- and diazepam-induced behavioral changes.

Methods

Various doses of an ethanolic extract of kava root or diazepam were administered intraperitoneally to BALB/cByJ inbred mice. Behavioral changes were measured in the mirrored chamber avoidance assay and elevated plus-maze assay. Reduced latency to enter and increased time spent in a normally avoided environment operationally defined anxiolysis. Sedation was defined by a significant decrease in locomotor activity in a circular arena.

Results

Kava extract produced statistically significant dose-dependent anxiolytic-like behavioral changes in both assays of anxiolysis. ED50 values for kava-induced increases in time spent inside the mirrored chamber and on the open arms of the plus maze were 125 mg/kg and 88 mg/kg, respectively. Kava extract also caused a profound decrease in locomotor activity (ED50 of 172 mg/kg). Flumazenil, a competitive benzodiazepine receptor antagonist, blocked both the anxiolytic and sedative effects of diazepam, but had no effect on kava's behavioral actions.

Conclusions

Kava extracts produce significant murine anxiolytic-like behavioral changes and sedation that are not mediated through the benzodiazepine binding site on the GABAA receptor complex.

Keywords

Kava Anxiety Sedation Mice Benzodiazepines 

Notes

Acknowledgements

This work was supported by a grant from the Presbyterian Health Foundation.

References

  1. Backhauß C, Krieglstein J (1992) Extract of kava (Piper methysticum) and its methysticin constituents protect brain tissue against ischemic damage in rodents. Eur J Pharmacol 215:265–269PubMedGoogle Scholar
  2. Baum SS, Hill H, Rommelspacher H (1998) Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 22:1105–1120CrossRefPubMedGoogle Scholar
  3. Boonen G, Häberlein H (1998) Influence of genuine kavapyrone enantiomers on the GABAA binding site. Planta Med 64:504–506PubMedGoogle Scholar
  4. Bowers BJ, Collins AC, Tritto T, Wehner JM (2000) Mice lacking PKC gamma exhibit decreased anxiety. Behav Genet 30:111–21CrossRefPubMedGoogle Scholar
  5. Carola V, D'Olimpio F, Brunamonti E, Mangia F, Renzi P (2002) Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behaviour in inbred mice. Behav Brain Res 134:49–57CrossRefPubMedGoogle Scholar
  6. Cao W, Burkholder T, Wilkins L, Collins AC (1993) A genetic comparison of behavioral actions of ethanol and nicotine in the mirrored chamber. Pharmacol Biochem Behav 45:803–809PubMedGoogle Scholar
  7. Crawley JN (1981) Neuropharmacological specificity of a simple animal model for behavioral actions of benzodiazepines. Pharmacol Biochem Behav 15:695–699PubMedGoogle Scholar
  8. Darragh A, Lambe R, Kenny M, Brick I, Taaffe W, O'Boyle C (1982) RO 15-1788 antagonizes the central effects of diazepam in man without altering diazepam bioavailability. Br J Clin Pharmacol 14:677–682Google Scholar
  9. Davies LP, Drew CA, Duffield P, Johnston GAR, Jameison DD (1992) Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol 71:120–126PubMedGoogle Scholar
  10. Dharmaratne HR, Nanayakkara NP, Khan IA (2002) Kavalactones from Piper methysticum, and their 13C NMR spectroscopic analyses. Phytochemistry 59:429–433CrossRefPubMedGoogle Scholar
  11. Dinh LD, Simmen U, Bueter KB, Bueter B, Lundstrom K, Schaffner W (2001) Interaction of various Piper methysticum cultivars with CNS receptors in vitro. Planta Med 67:306–311CrossRefPubMedGoogle Scholar
  12. Duffield AM, Lidgard RO (1986) Analysis of kava resin by gas chromatography and electron impact and methane negative ion chemical ionization mass spectrometry. Biomed Mass Spectrom 13:621–626Google Scholar
  13. Duffield AM, Lidgard RO, Low GK-C (1986) Analysis of the constituents of Piper methysticum by gas chromatography methane chemical ionization mass spectrometry. Biomed Mass Spectrom 13:303–313Google Scholar
  14. Duffield PH, Jamieson DD, Duffield AM (1989) Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats. Arch Int Pharmacodyn Ther 301:81–90PubMedGoogle Scholar
  15. Feger B, Boonen G, Haberlein H, Kuschinsky K (1998) In vivo microdialysis study of (±)-kavain on veratridine-induced glutamate release. Eur J Pharmacol 347:211–214PubMedGoogle Scholar
  16. Friese J, Gleitz J (1998) Kavain, dihydrokavain and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A20-α-benzoate to receptor site 2 of voltage-gates Na+ channels. Planta Med 64:458–459PubMedGoogle Scholar
  17. Gallup GG Jr (1968) Mirror-image stimulation. Psychol Bull 70:782–793PubMedGoogle Scholar
  18. Ganzera M, Khan IA (1999) Analytical techniques for determination of lactones in Piper methysticum Forst. Chromatographia 50:649–653Google Scholar
  19. Garrett KM, Niekrasz I, Haque D, Parker KM, Seale TW (1998) Genotypic differences between C57BL/6 and A inbred mice in anxiolytic and sedative actions of diazepam. Behav Genet 28:125–136Google Scholar
  20. Gleitz J, Friese J, Beile A, Ameri A, Peters T (1996) Anticonvulsive action of (±)-kavain estimated from its properties on stimulated synaptosomes and Na+ channel receptor sites. Eur J Pharmacol 315:89–97CrossRefPubMedGoogle Scholar
  21. Griebel G, Belzung C, Perrault G, Sanger DJ (2000) Differences in anxiety-related behaviors and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148:164–170PubMedGoogle Scholar
  22. Handley SL, Mithani S (1984) Effects of alpha-adrenoreceptor agonists and antagonists in a maze exploration model of "fear"-motivated behavior. Naunyn-Schmiedeberg's Arch Pharmacol 327:1–5Google Scholar
  23. Houri D (1986) Effects of central acting drugs on the mirror staircase test. Nippon Yaturigaku Zasshi 87:135–142Google Scholar
  24. Hunkeler W, Mohler H, Pieri L, Polc P, Bonetti EP, Cumin R, Schaffner R, Haefely W (1981) Selective antagonists of benzodiazepines. Nature 290:514–516PubMedGoogle Scholar
  25. Jamieson DD, Duffield PH (1990) The antinociceptive actions of kava components in mice. Clin Exp Pharmacol Physiol 17:495–508PubMedGoogle Scholar
  26. Jamieson DD, Duffield PH, Cheng D, Duffield AM (1989) Comparison of the central nervous system activity of the aqueous and lipid extract of kava (Piper methysticum). Arch Int Pharmacodyn Ther 301:66–80PubMedGoogle Scholar
  27. Jussofie A, Schmiz A, Hiemke C (1994) Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of the brain. Psychopharmacology 116:469–474PubMedGoogle Scholar
  28. Kaul PN, Joshi BS (2001) Alternative medicine: Herbal drugs and their critical appraisal—Part II. Prog Drug Res 57:1–75PubMedGoogle Scholar
  29. Keledjian J, Duffield PH, Jameison DD, Lidgard RO, Duffield AM (1988) Uptake into mouse brain of four compounds present in the psychoactive beverage kava. J Pharm Sci 77:1003–1006PubMedGoogle Scholar
  30. Keller K, Klohs MW (1963) A review of the chemistry and pharmacology of the constituents of Piper methysticum. Lloydia 26:1–15Google Scholar
  31. Kretzschmar H, Meyer HJ, Teschendorf HJ (1970) Strychnine antagonistic potency of pyrone compounds of the kavaroot (Piper methysticum Forst.). Experientia 26:283–284PubMedGoogle Scholar
  32. Lembert EM (1967) Secular use of kava in Tonga. Q J Stud Alcohol 28:328–341PubMedGoogle Scholar
  33. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology 92:180–185PubMedGoogle Scholar
  34. Maura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA (1997) Kava extract ingredients, (+)methysticin and (±)kavain inhibit voltage-operated Na+-channels in rat CA1 hippocampal neurons. Neuroscience 81:345–351CrossRefPubMedGoogle Scholar
  35. Martin HB, Stofer WD, Eichinger MR (2000) Kavain inhibits murine airway smooth muscle contraction. Planta Med 66:601–606CrossRefPubMedGoogle Scholar
  36. McDowall A, Owen S, Robin AA (1966) A controlled comparison of diazepam and amylobarbitone in anxiety states. Br J Psychiatry 112:629–631PubMedGoogle Scholar
  37. Mohler H, Okada T (1977) Benzodiazepine receptor: demonstration in the central nervous system. Science 198:849–851PubMedGoogle Scholar
  38. National Institutes of Health (1996) Guide for the Care and Use of Laboratory Animals. National Academies PressGoogle Scholar
  39. Montgomery KC (1958) The relation between fear induced by novel; stimulation and exploratory behavior. J Comp Physiol Psychol 48:254–260Google Scholar
  40. Norton SA (1998) Herbal medicines in Hawaii from tradition to convention. Hawaii Med J 57:382–385PubMedGoogle Scholar
  41. O'Hara MJ, Kinnard WJ, Buckey JP (1965) preliminary characterization of aqueous extracts of Piper methysticum (kava, kava kava). J Pharm Sci 54:1021–1025PubMedGoogle Scholar
  42. Patel JB, Martin C, Malick JB (1982) Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur J Pharmacol 86:295–298CrossRefPubMedGoogle Scholar
  43. Pellow S, Chopin P, File SE (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Meth 14:149–167PubMedGoogle Scholar
  44. Pittler MH, Ernst E (2000) Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 20:84–89Google Scholar
  45. Rex A, Morgenstern E, Fink H (2002) Anxiolytic-like effects of kava-kava in the elevated plus maze test—a comparison with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 26:855–860CrossRefPubMedGoogle Scholar
  46. Rodgers RJ, Johnson JT (1995) Factor analysis of spatiotemporal and ethological measures in the murine elevated plus-maze test of anxiety. Pharmacol Biochem Behav 52:297–303PubMedGoogle Scholar
  47. Schirrmacher K, Busselberg D, Langosch JM, Walden J, Winter U, Bingmann D (1999) Effects of (±)-kavain on voltage-activated inward currents of dorsal root ganglion cells from neonatal rats. Eur Neuropsychopharmacol 9:171–176CrossRefPubMedGoogle Scholar
  48. Seale TW, Garrett KM (1995) Genotype-dependent heterogeneity in basal activity and benzodiazepine-induced alteration in anxiety-like behaviors. Behav Genet 25:287Google Scholar
  49. Seale TW, Niekrasz I, Garrett KM (1996) Anxiolysis by ethanol, diazepam and buspirone in a novel murine behavioral assay. Neuroreport 7:1803–1808PubMedGoogle Scholar
  50. Seitz U, Schüle A, Gleitz J (1997) [3H]-Monoamine uptake inhibition properties of kava pyrones. Planta Med 63:548–549PubMedGoogle Scholar
  51. Shulgin AT (1973) The narcotic pepper—the chemistry and pharmacology of Piper methysticum and related species. Bull Narc 25:59–74Google Scholar
  52. Singh YN (1992) Kava: an overview. J Ethnopharmacol 37:13–45PubMedGoogle Scholar
  53. Smith KK, Ranjith H, Dharmaratne W, Feltenstein MW, Broom SL, Roach JT, Nanyakkara NP, Khan IA, Sufka KJ (2001) Anxiolytic effects of kava extract and kavalactones in the chick social separation-stress paradigm. Psychoparmacology 155:86–90CrossRefGoogle Scholar
  54. Squires RF, Braestrup C (1977) Benzodiazepine receptors in rat brain. Nature 266:732–734PubMedGoogle Scholar
  55. Toubas PL, Alba KA, Cao W, Seale TW (1990) Latency to enter a mirrored chamber: a novel behavioral assay for anxiolytic agents. Pharmacol Biochem Behav 35:121–126CrossRefPubMedGoogle Scholar
  56. Vogel JR, Beer B, Clody DE (1971) A simple and reliable conflict procedure for testing anti-anxiety agents. Psychopharmacologia 21:1–7Google Scholar

Copyright information

© Springer-Verlag 2003

Authors and Affiliations

  • Kennon M. Garrett
    • 1
  • Garo Basmadjian
    • 2
  • Ikhlas A. Khan
    • 3
  • Brian T. Schaneberg
    • 3
  • Thomas W. Seale
    • 4
  1. 1.Department of PhysiologyUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  2. 2.Department of Pharmaceutical SciencesUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA
  3. 3.National Center for Natural Products Research, School of PharmacyUniversity of MississippiUniversityUSA
  4. 4.Department of PediatricsUniversity of Oklahoma Health Sciences CenterOklahoma CityUSA

Personalised recommendations